Finally, statins can overcome the resistance to EGFR tyrosine kinase inhibitors in a non-small cell lung cancer cells (183) and to gefitinib in KRAS-mutant human non-small cell lung cancer cells (230). The gene discussed is KRAS; the disease is non-small cell lung carcinoma.